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Commentaries on Viewpoint: The ongoing need for good physiological
investigation: Obstructive sleep apnea in HIV patients as a paradigm
HIV, OBSTRUCTIVE SLEEP APNEA, AND LIPODYSTROPHY: A 
COMPREHENSIVE APPROACH
TO THE EDITOR: The intriguing paradigm put forth by Darquenne et 
al. (3) highlighted that improved therapy against human 
immunodeﬁciency virus (HIV) has come at the cost of elevated 
rates of chronic diseases, such as obstructive sleep apnea 
(OSA) and obesity, during the highly active antiretroviral 
therapy (HAART) era. Indeed, obesity in HIV-infected indi-
viduals, especially women, has been rising (1). In a study by 
Crum-Cianﬂone et al. (2), 63% of HIV-infected patients in 
multiple HIV clinics were overweight/obese. In addition, lip-
odystrophy in HIV patients is a likely cause of OSA (2, 5), and 
thus increased obesity and neck circumference in HIV patients 
lead to prevalence of OSA (3, 5).
We agree that understanding HIV patient populations and 
their respective risk factors, as suggested by Darquenne et al.
(3), is essential for effective antiretroviral therapy. Speciﬁcally, 
it is our belief that treating obese HIV-infected individuals 
necessitates a more thorough understanding of 
lipohypertrophy predisposition, as well as pharmacological 
treatment options. An example carried out by Edgeworth et 
al. (4), which suggests the potential beneﬁt of 
thiazolidinediones in lipodystrophy treatment through fat 
redistribution, offers a combined ap-proach that could 
simultaneously manage a patient’s HIV and OSA symptoms (3).
In our view, thorough studies that examine the 
overlap between HAART, OSA, and an individual’s 
susceptibility to lipohypertrophy will be paramount to 
improving the lives of a large proportion of HIV-infected 
patients. However, based on preliminary results, clinical 
application in a large-scale setting has not yielded consistent 
outcomes (4).
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COMMENT ON VIEWPOINT: “THE ONGOING NEED FOR GOOD 
PHYSIOLOGICAL INVESTIGATION: OBSTRUCTIVE SLEEP APNEA IN 
HIV PATIENTS AS A PARADIGM”
TO THE EDITOR: We congratulate Darquenne et al. (2) on their 
Viewpoint article highlighting the need for rigorous research 
investigating the relationship of obstructive sleep apnea (OSA) 
and human immunodeﬁciency virus (HIV). Such research 
poses a unique challenge in light of the multivariate etiology 
of OSA that is highly individualized (3). Yet, considering that 
Patil et al. (4) found that body mass index adjusted analyses 
marginalized the differences in sleep-disordered breathing 
(SDB) observed between HIV� and HIV� men, and even among 
HIV� men using highly active antiretroviral therapy (HAART) 
and those who do not, we wonder if this phenom-enon is not 
primarily adipose related. This phenomenon war-rants 
investigation into HAART regimens that include protease 
inhibitors vs. those that do not, because it is mainly the 
protease inhibitors as a class that induce perturbations in lipid 
metabolism relative to the other classes of HAART (1). Aside 
from lipid effects, we contend that no differences in 
physiology of SDB will likely be observed among HIV� 
(HAART� or HAART�) and HIV� individuals with appropriately 
adjusted analyses. Considering this point, how would 
management of HIV� patients with SDB differ from an HIV� 
individual with SDB? Therefore, it is imperative that the 
investigation of the integrative physiology of HIV and OSA 
must ﬁrst address the role of BMI (quite literally, the 
“elephant in the room!”).
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COMMENT ON THE ONGOING NEED FOR GOOD PHYSIOLOGICAL 
INVESTIGATION: OBSTRUCTIVE SLEEP APNEA IN HIV PATIENTS AS 
A PARADIGM
TO THE EDITOR: Darquenne et al. (3) propose an interesting 
theoretical framework for linking HIV infection with a high 
prevalence of obstructive sleep apnea, emphasizing on 
the physiopathological role of antiretroviral therapy.
However, a first debatable and central point of discussion is
that the existence of a higher prevalence of obstructive sleep
apnea in HIV-infected than in uninfected patients is unsup-
ported by existing relevant bibliography. Three recent studies
in fact indicate that this would not be the case (2, 4, 5). All
these studies show a prevalence of obstructive sleep apnea that
is slightly higher in HIV-uninfected patients than in the HIV-
infected group (5). Kunisaki et al. (4) reported a cohort of
3,641 HIV-uninfected and 3,683 HIV-infected patients, show-
ing a prevalence of obstructive sleep apnea of 12.4 and 3.9%,
respectively.
A second disputable point is to assign to antiviral therapy a
major causal responsibility for obstructive sleep apnea. Un-
treated HIV-infected patients show a prevalence for obstructive
sleep apnea that is similar to those receiving antiretroviral
therapy (2, 4, 5). This may suggest that antiretroviral therapy is
not a strong risk factor for development of obstructive sleep
apnea. Finally, it is not reasonable to disregard the possible role
of HIV associated neuroinflammation (2) and denervation (1)
in the pathogenesis of obstructive sleep apnea.
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ACTIVATION OF RENIN-ANGIOTENSIN SYSTEM: A
POTENTIAL LINK BETWEEN ANTIRETROVIRAL THERAPY
AND OBSTRUCTIVE SLEEP APNEA
TO THE EDITOR: The article by Darquenne and colleagues (3)
highlights the importance of integrative physiology to under-
stand different complications associated with antiretroviral
therapy (ART). The authors point out that human immunode-
ficiency virus (HIV) infection and obstructive sleep apnea
(OSA) are independently linked to increased cardiovascular
disease risk. In this regard, the interaction of ART, OSA, and
renin-angiotensin system (RAS) peptides needs to be consid-
ered. Chronic intermittent hypoxia (IH), a characteristic of
OSA, leads to sustained elevation of sympathetic activity and
blood pressure (BP) (5). In humans, the increase in blood
pressure after exposure to IH is abolished by blockade of the
angiotensin II AT1R, suggesting an important role for the RAS
in the pathophysiology of hypertension associated with IH (4).
Endogenous angiotensin peptides acting in sympathetic pre-
motor neurons contribute to IH-induced increases in BP ob-
served in a model of sleep apnea-induced hypertension (2).
Part of the antiretroviral therapy includes HIV protease inhib-
itors (PIs). The effect of PIs on the enzymatic cascade of the
RAS remains to be investigated. Interestingly, evidence indi-
cates that HIV patients using PIs develop a metabolic syn-
drome including insulin resistance, lipodystrophy, and hyper-
tension and at least part of the mechanism involves activation
of the RAS (1). Therefore, the choice for PIs could activate
RAS exacerbating the sympathetic output in HIV patients with
OSA contributing to development of cardiovascular disease.
Altogether, these observations suggest a complex interaction of
factors in patients under ART therapy, leading to a vicious
cycle that can only be explained through integrative physiol-
ogy.
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HIV INFECTION AND OBSTRUCTIVE SLEEP APNEA: WHY
EPIDEMIOLOGICAL DATA ARE NEEDED
TO THE EDITOR: The Viewpoint article makes a case that HIV-
infected patients should be assessed more frequently and more
carefully for obstructive sleep apnea (OSA) (1). However, as
for other non-AIDS complications, international epidemiolog-
ical work is needed to determine the best prevalence and
incidence disease estimates. Indeed, the case of cardiovascular
diseases (CVD) in HIV populations shows that such data are
needed to anticipate adequate health care response as risk
evolves rapidly. Large epidemiological studies have found that
CVD incidence is actually decreasing in particular for arterio-
sclerotic disease in HIV disease. The use of less cardiotoxic
antiretrovirals as well as preventative measures for CVD are
probably responsible for such a decrease (5). In addition,
further data show that CVD events are less likely in those who
have not experienced immune depression (4).
Furthermore, a recent study (3) that was not referenced in
the Viewpoint found that the prevalence of OSA in the Veter-
ans Aging Cohort Study is lower than in age-comparable
controls, even with correction for traditional OSA risk factors
(age and BMI). This further highlights the need for large
international studies that rigorously assess the effect of OSA,
multiple comorbidities, as well as their intricate demographic
mediators (2), including survivor bias. Although we agree that
optimal physiological investigation is needed in HIV-infected
patients, particularly for OSA as suggested by the Viewpoint’s
title, the real issue is that robust epidemiological estimates of
OSA prevalence and incidence are needed. This is important
because there are many competing non-AIDS complications in
chronic HIV infection.
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COMMENTS ON “VIEWPOINT CALL FOR COMMENTS: THE
ONGOING NEED FOR GOOD PHYSIOLOGICAL
INVESTIGATION: OBSTRUCTIVE SLEEP APNEA IN HIV
PATIENTS AS A PARADIGM,” ADDING CENTRAL SLEEP
APNEA AND PERIODIC BREATHING TO THE PICTURE
TO THE EDITOR: We read with great interest the work from
Darquenne and colleagues (1) suggesting the need of integra-
tive physiology analysis to understand potential mechanisms
for OSA in HIV patients. As mentioned by the authors, the
prevalence of OSA among HIV-infected persons has been
surprisingly high even among those who are not obese. Know-
ing that among other complications, HIV patients experience
instability in ventilatory control and neurological damages and
that HIV infection is associated with impaired cardiovascular
risk, we suggest that periodic breathing might also play a key
factor in the observed amount of SDB in HIV patients. This
might look contradictory given the low proportion of central
events (11  20%) observed in HIV patients by Patil and
colleagues (4). It should be noted that although several authors
such as Tkacova and colleagues (5) have already concluded
that in some patients with heart failure, OSA and CSA are part
of a spectrum of periodic breathing that can shift over time. In
another study by Hoffman and Schulman (3) on the appearance
of CSA after treatment of OSA, the authors indicate that there
is evidence that many laboratories treat respiratory events as if
they were obstructive, when in fact they pathophysiologically
may be closer to central. We therefore suggest the use of tools
capable of detecting periodical instability beyond CSA or OSA
cases (2). Once periodic breathing has been identified, the
associated loop gain, or its periodicity, might open a new
window of information: a wider integrative physiology ap-
proach to understand SDB in HIV patients.
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RESPONSE TO DARQUENNE ET AL.
TO THE EDITOR: In their Viewpoint, Darquenne et al. (2) focus
on the role of obstructive sleep apnea (OSA) as one non-
AIDS condition complicating health issues in HIV-infected
patients. Their conclusion advocates the importance of in-
tegrative physiology to understand chronic diseases with
a view toward improving the lives of persons living with
HIV.
We concur that understanding pathophysiologic mecha-
nisms is essential to any contemporary biotechnological rep-
ertoire, thus emphasizing the need to follow principles derived
from advances in physiology.
However, within the logic of the approach in their View-
point, OSA ranks low within the list of conditions following
in the wake of antiretroviral therapy. With the focus on OSA
alone, the problem is losing proportions because the impact
of diseases such as diabetes, cardiovascular disorders, and
malignancies outweigh OSA as a contributor to major health
risks.
In our view, this report insufficiently captures the overall
impact of reported findings. Indeed, there is a plethora of
literature on the deleterious interaction of diabetes and depres-
sion alone (5) and also that between sleep orders and mental
health (1). Additionally, our criticism concerns the role of
symptoms such as fatigue, prevalent in HIV-infected patients
as well as in large patient groups diagnosed with functional
somatic syndromes (4).
Therefore, one is well advised to concede that in condi-
tions fraught with somatic and mental health diagnoses such
as HIV, any pathophysiological assessment is preferably
guided by the model proposed by Engel (3). Although this
paper dates from 1977, we think its ideas have lost nothing
of its actuality.
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COMMENT ON: THE ONGOING NEED FOR GOOD
PHYSIOLOGICAL INVESTIGATION: OBSTRUCTIVE SLEEP
APNEA IN HIV PATIENTS AS A PARADIGM
TO THE EDITOR: The article by Darquenne et al. (2) uses sleep-
related problems in HIV to illustrate their main thesis, but the
principles of their Viewpoint have much broader implications.
In that spirit we address another example where physiology is
critical to best medical practice.
Treatment of the acute respiratory distress syndrome
(ARDS) is exceptionally complex because in addition to the
primary injury such as trauma, sepsis, or pneumonia that
initiates the disease process, a secondary ventilator induced
lung injury (VILI) is believed to drive progressive lung injury
ultimately resulting in ARDS (5). Darquenne et al. (2) high-
light the essential need for good physiologic investigation to
identify the mechanisms in complex pathologic diseases such
as ARDS/VILI. Our group has taken a solid physiologic
approach to investigating not only the mechanisms of VILI but
also the possibility of developing a mechanical breath that
could be used as a therapeutic tool to prevent ARDS before it
develops (1, 4). Unlike reductionist studies that focus on a
blocking a single molecular mediator to prevent ARDS or VILI
using small animal models, we looked at the impact the
mechanical breath on multiple physiologic components includ-
ing: 1) lung and chest wall mechanics, 2) lung fluid balance, 3)
alveolar microstrain (3), and 4) pulmonary surfactant function
in a high fidelity, clinically applicable porcine ARDS model
(4). We demonstrated that an extended time at inspiration and
minimal time at end expiration using airway pressure release
ventilation (APRV) preserves surfactant function, maintains
lung fluid balance preventing edema, and normalizes lung
mechanics, which when combined, prevent ARDS (4). These
studies strongly support the need of an integrative physiologic
approach to solve complex clinical problems; indeed our work
recently showed that preemptive APRV works clinically, pre-
venting ARDS in humans (1).
REFERENCES
1. Andrews PL, Shiber JR, Jaruga-Killeen E, Roy S, Sadowitz B, O’Toole
RV, Gatto LA, Nieman GF, Scalea T, Habashi NM. Early application of
airway pressure release ventilation may reduce mortality in high-risk
trauma patients: a systematic review of observational trauma ARDS liter-
ature. J Trauma Acute Care Surgery 75: 635–641, 2013.
2. Darquenne C, Hicks C, Malhotra A. Viewpoint: The ongoing need for
good physiological investigation: obstructive sleep apnea in HIV patients as
a paradigm. J Appl Physiol; doi:10.1152/japplphysiol.00656.2014.
3. Kollisch-Singule M, Emr B, Smith B, Roy S, Jain S, Satalin J, Snyder
K, Andrews P, Habashi N, Bates J, Marx W, Nieman G, Gatto LA.
Mechanical breath profile of airway pressure release ventilation: the effect
on alveolar recruitment and microstrain in acute lung injury. JAMA Surg, in
press.
4. Roy S, Habashi N, Sadowitz B, Andrews P, Ge L, Wang G, Roy P,
Ghosh A, Kuhn M, Satalin J, Gatto LA, Lin X, Dean DA, Vodovotz Y,
Nieman G. Early airway pressure release ventilation prevents ARDS-a
novel preventive approach to lung injury. Shock 39: 28–38, 2013.
5. Serpa Neto A, Cardoso SO, Manetta JA, Pereira VG, Espósito DC,
Pasqualucci Mde O, Damasceno MC, Schultz MJ. Association between
use of lung-protective ventilation with lower tidal volumes and clinical
outcomes among patients without acute respiratory distress syndrome: a
meta-analysis. JAMA 308: 1651–1659, 2012.
Gary Nieman
Department of Surgery Upstate Medical University
Syracuse, New York
Louis A. Gatto
Department of Biology
SUNY Cortland
Cortland, New York
